Sample details

PPMI-PD is designed to identify clinical, imaging, genetic and biospecimen markers of Parkinson's disease (PD) progression. At baseline, participants were at least 30 years old, had a clinical diagnosis of Parkinson's Disease (PD), and had a positive dopamine transporter single photon emission tomography (SPECT) result. They were recruited within 7 years of diagnosis. Over 700 participants were recruited for the study. Among the participants, over 400 were not being treated for PD despite having received a diagnosis, and almost 300 had rare genetic variants.

Study design

Cohort - clinical

Number of participants at first data collection

717

Age at first data collection

≥ 30 years

Participant year of birth

Varied

Participant sex

MF

Representative sample

No

Sample features

People with mild and major neurocognitive disorders

Dataset details

Country

Austria

Year of first data collection

2025-05-09T15:16:11.407000+00:00

Primary institutions

Institute for Neurodegenerative Disorders (INDD)

Links

Primary URL

Profile on aggregate site

Aggregate profile URL

Funders

Michael J. Fox Foundation for Parkinson's Research

Ongoing?

Yes

Data types collected

Standard measures